Description

Diclak ID (diclofenac) tablets with modified release 150 mg. №20

Ingredients

Active ingredient: Each tablet contains 150 mg of diclofenac with modified release.

Dosage

Recommended dosage: The usual dose is one tablet daily, swallowed whole with water, preferably with food.

Indications

Indicated for: Relief of pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute gout.

Contraindications

Do not use if: Allergic to diclofenac, have a history of gastrointestinal bleeding, or in the third trimester of pregnancy.

Directions

Directions for use: Follow the instructions provided by your healthcare provider. Do not exceed the recommended dose.

Scientific Evidence

Diclofenac, the active ingredient in Diclak ID tablets, is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting the enzyme cyclooxygenase, thereby reducing the production of prostaglandins involved in inflammation, pain, and fever. Studies have shown diclofenac to be effective in managing various inflammatory conditions, with modified-release formulations offering prolonged pain relief and improved patient compliance.

Additional Information

Diclak ID tablets with modified release provide a convenient once-daily dosing option for individuals requiring long-term pain management. It is important to note that NSAIDs like diclofenac may increase the risk of cardiovascular events and gastrointestinal complications, especially with prolonged use or in high doses. Consult your healthcare provider for personalized advice on the use of this medication.

Pharmacological Effects and Clinical Trials

Diclofenac exerts its pharmacological effects by inhibiting prostaglandin synthesis, which leads to decreased inflammation, pain, and fever. The modified-release formulation of Diclak ID ensures a sustained drug release, maintaining therapeutic levels in the body for extended periods, thereby providing prolonged analgesic and anti-inflammatory effects.

Clinical trials have demonstrated the efficacy of diclofenac in managing various painful conditions, including arthritis and musculoskeletal disorders. A study published in the Journal of Clinical Pharmacology highlighted the superior pain relief and functional improvement achieved with diclofenac compared to placebo in patients with osteoarthritis. Additionally, a meta-analysis in the Cochrane Database of Systematic Reviews supported the use of diclofenac for acute gout attacks, showing significant pain reduction and improved joint function.

Overall, the pharmacological profile and clinical evidence support the use of Diclak ID tablets with modified release 150 mg as an effective option for individuals requiring long-term pain relief with reduced dosing frequency.